Rituximab for linear IgA bullous dermatosis

Abstract

Linear IgA Bullous Dermatosis (LABD) is an idiopathic or drug-induced vesiculobullous disease typically managed with dapsone or colchicine. We report a case of LABD successfully treated with rituximab who was intolerant of first-line therapies and recalcitrant to typical immunosuppressants. The patient was initially started on prednisone and mycophenolate mofetil which resulted in minimal response and disease progression. Improvement was seen after two infusions of rituximab 1000mg at two weeks apart with planned maintenance therapy.

Keywords

• Linear IgA bullous dermatosis
• rituximab
• sulfa allergy
• recalcitrant
• blistering diseases